JP2004534820A - 鼻うっ血および鼻閉塞の処置のための抗ヒスタミン薬 - Google Patents

鼻うっ血および鼻閉塞の処置のための抗ヒスタミン薬 Download PDF

Info

Publication number
JP2004534820A
JP2004534820A JP2003506909A JP2003506909A JP2004534820A JP 2004534820 A JP2004534820 A JP 2004534820A JP 2003506909 A JP2003506909 A JP 2003506909A JP 2003506909 A JP2003506909 A JP 2003506909A JP 2004534820 A JP2004534820 A JP 2004534820A
Authority
JP
Japan
Prior art keywords
day
amount
desloratadine
allergic
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003506909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534820A5 (es
Inventor
ルイス エム． サルムン，
パトリシア ローアン，
リチャード アール． ローバー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2004534820A publication Critical patent/JP2004534820A/ja
Publication of JP2004534820A5 publication Critical patent/JP2004534820A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003506909A 2001-06-20 2002-06-19 鼻うっ血および鼻閉塞の処置のための抗ヒスタミン薬 Pending JP2004534820A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29963601P 2001-06-20 2001-06-20
US29963701P 2001-06-20 2001-06-20
PCT/US2002/019414 WO2003000264A1 (en) 2001-06-20 2002-06-19 Antihistamines for the treatment of nasal congestion and nasal obstruction

Publications (2)

Publication Number Publication Date
JP2004534820A true JP2004534820A (ja) 2004-11-18
JP2004534820A5 JP2004534820A5 (es) 2005-08-18

Family

ID=26971322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003506909A Pending JP2004534820A (ja) 2001-06-20 2002-06-19 鼻うっ血および鼻閉塞の処置のための抗ヒスタミン薬

Country Status (9)

Country Link
EP (1) EP1401444A1 (es)
JP (1) JP2004534820A (es)
CN (1) CN1518448A (es)
BR (1) BR0210534A (es)
CA (1) CA2450583A1 (es)
HU (1) HUP0401630A2 (es)
MX (1) MXPA03011705A (es)
NO (1) NO20035706D0 (es)
WO (1) WO2003000264A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633359A1 (en) * 2003-05-28 2006-03-15 Ucb Farchim S.A. Use of efletirizine for treating persistent allergic rhinitis
CN100444841C (zh) * 2004-11-10 2008-12-24 鲁南制药集团股份有限公司 氯雷他定的外用制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
DE4394931T1 (de) * 1992-09-03 1995-07-20 Sepracor Inc Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
BR9407414A (pt) * 1993-09-07 1996-11-12 Procter & Gamble Composições contendo um sal de aminoácido de agente antiinflamatório não-esteroide de ácido propiônico e pelo menos um descongestionante um expectorante um anti-histamina e um antitussivo
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
WO1998018470A1 (en) * 1996-10-31 1998-05-07 Schering Corporation Composition, for the treatment of asthma, containing loratadine and a decongestant
JP2001517626A (ja) * 1997-09-19 2001-10-09 ザ、プロクター、エンド、ギャンブル、カンパニー 呼吸疾患を治療するための組成物及び方法
WO1999032125A1 (en) * 1997-12-23 1999-07-01 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6248308B1 (en) * 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
ATE311928T1 (de) * 1998-07-01 2005-12-15 Warner Lambert Co (-)-pseudoephedrin als sympathomimetisches arzneimittel
WO2000050015A1 (en) * 1999-02-23 2000-08-31 Yuhan Corporation Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU3800601A (en) * 2000-02-03 2001-08-14 Schering Corporation Treating allergic and inflammatory conditions
PE20020324A1 (es) * 2000-10-06 2002-06-18 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina

Also Published As

Publication number Publication date
HUP0401630A2 (hu) 2004-12-28
EP1401444A1 (en) 2004-03-31
BR0210534A (pt) 2004-06-22
CN1518448A (zh) 2004-08-04
CA2450583A1 (en) 2003-01-03
MXPA03011705A (es) 2004-03-19
NO20035706D0 (no) 2003-12-19
WO2003000264A1 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
US20060276495A1 (en) Treatment methods of nasal congestion and nasal obstruction
US7902208B2 (en) Treating allergic and inflammatory conditions
CN1235545A (zh) 含有氯雷他定和减充血剂的用于治疗哮喘的组合物
US6432972B2 (en) Treating allergic and inflammatory conditions
Bunnag et al. A double‐blind comparison of nasal budesonide and oral astemizole for the treatment of perennial rhinitis
JP2004534820A (ja) 鼻うっ血および鼻閉塞の処置のための抗ヒスタミン薬
Kaiser et al. Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis
Corren et al. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions
US20040138247A1 (en) Use of desloratadine for treating allergic and inflammatory conditions
AU2002315357A1 (en) Antihistamines for the treatment of nasal congestion and nasal obstruction
WO2001021162A2 (en) Treating allergic and inflammatory conditions using desloratadine
EP1239859A2 (en) Use of desloratadine for treating allergic and inflammatory conditions in pediatric patients
US20050203117A1 (en) Treating allergic and inflammatory conditions
US20030004179A1 (en) Treating allergic and inflammatory conditions
US20060154948A1 (en) Treating allergic and inflammatory conditions
AU2006201218A1 (en) Treating allergic and inflammatory conditions
Grigor'evna Clinical and pharmacological peculiarities of cetirizine use for the therapy of allergic diseases in children Author affiliation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091023